• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Imperative Care Completes Initial Closing of Series E Financing for up to $150 Million; Shacey Petrovic Appointed to Vice Chair, Board of Directors

    7/25/24 8:00:00 AM ET
    $EXAS
    $PODD
    Medical Specialities
    Health Care
    Medical/Dental Instruments
    Health Care
    Get the next $EXAS alert in real time by email

    Financing Fuels the Company's Hypergrowth to Make Elevated Care Accessible to More Patients

    Petrovic's Appointment Positions Imperative Care for Long Term Success and Scale

    Imperative Care, Inc., a medical technology company developing connected innovations to elevate care for people affected by stroke and other ischemic diseases, today announced the initial close of an oversubscribed Series E financing.

    The financing was led by Ally Bridge Group with participation from other existing investors, including D1 Capital Partners, AMED Ventures, Bain Capital Life Sciences, Rock Springs Capital Management LP, Innovatus Capital Partners, LLC and Pura Vida Investments. The financing also included participation from new investors, including Catalio Capital Management, LP, HealthCor Family Office, Montreux Growth Partners, and INTAI Technology Corp.

    "We are grateful for the continued support of our existing investors and welcome our new investors who share our vision for leadership in stroke and vascular thrombectomy," said Fred Khosravi, Chairman and CEO of Imperative Care. "This latest financing fuels our hypergrowth strategy as we work to make better care accessible to more patients. We will continue to invest in novel technologies and clinical evidence to measure the impact of these technologies on patient outcomes."

    "As investors in Imperative Care since the company's Series C financing in December 2019, we have been impressed with the dramatic progress the company has made on many fronts, including treating more than 45,000 patients with life-saving technologies," said Ally Bridge founder and CEO Frank Yu, who has also served as a Director on the Imperative Care Board since 2019. "We are excited to support the next stage of Imperative Care's success, as the company strengthens its position for treating ischemic stroke and prepares to make a major contribution to the treatment of peripheral vascular disease."

    After the initial closing and subject to the discretion of the Company, there may be additional closings of this Series E financing, raising up to $150 million in total.

    Appointment of Shacey Petrovic to Vice Chair, Board of Directors

    The company also announced the appointment of Shacey Petrovic to the newly created position of Vice Chair of its Board of Directors. Petrovic joined the Imperative Care Board in 2023. In the role of Vice Chair, Petrovic will focus on strategies to scale the company with the goal of bringing life-changing technologies to more patients suffering from stroke and other devastating vascular diseases.

    Petrovic also serves on the Boards of Exact Sciences (NASDAQ:EXAS), Ambu A/S (OTC US: AMBBY) and Axena Health. Previously, Petrovic served on the board and was President and CEO of Insulet Corporation (NASDAQ:PODD), a diabetes technology company. Under her leadership, Insulet grew to serve hundreds of thousands of people with diabetes across the globe.

    "It has been a privilege to benefit from Shacey's business acumen and strategic mastery as we position Imperative Care for long term success and scale," Khosravi said. "On behalf of our Board of Directors, I would like to congratulate Shacey on her appointment to Vice Chair as we continue to build the thrombectomy company of the future with the patient at the center."

    "I am excited to step into this new leadership role as Imperative Care accelerates its work to deliver impactful innovations to patients at the most tenuous moments of their lives," said Petrovic. "My experience serving on the Imperative Care Board has been quite inspirational as the company engineers solutions to some of the greatest challenges in medicine through medtech and digital health innovations."

    About Imperative Care, Inc.

    Imperative Care is a commercial-stage medical technology company researching and developing connected innovations to elevate care for people affected by devastating vascular diseases such as stroke and pulmonary embolism. The company is focused on addressing specific gaps in treatment and care to make an impact across the entire patient journey. Imperative Care is based in Campbell, Calif. https://imperativecare.com

    Legal Disclaimer / Forward-Looking Statements

    This press release is not an offer to sell securities or a solicitation of an offer to buy any securities, and may not be relied upon in connection with the purchase or sale of any company security. This release may contain forward-looking statements regarding plans for future financing, projected business performance, future innovations and improvement of patient outcomes. Such statements are forward-looking statements and there can be no assurance that the results stated or implied by these forward-looking statements will actually be realized or achieved by the company. Forward-looking statements may be based on management assumptions that could prove to be wrong. The company's predictions may not be realized for a variety of reasons as the company's business is subject to substantial risks and potential events beyond its control that could cause material differences between predicted and actual results.

    View source version on businesswire.com: https://www.businesswire.com/news/home/20240725822876/en/

    Get the next $EXAS alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $EXAS
    $PODD

    CompanyDatePrice TargetRatingAnalyst
    Insulet Corporation
    $PODD
    5/20/2026Outperform
    William Blair
    Insulet Corporation
    $PODD
    4/24/2026$220.00Buy → Neutral
    Rothschild & Co Redburn
    Insulet Corporation
    $PODD
    4/7/2026$230.00Buy → Neutral
    Citigroup
    Insulet Corporation
    $PODD
    1/27/2026$294.00Hold
    TD Cowen
    Exact Sciences Corporation
    $EXAS
    1/20/2026$105.00Outperform → Neutral
    Mizuho
    Insulet Corporation
    $PODD
    1/12/2026$274.00Overweight → Equal Weight
    Barclays
    Exact Sciences Corporation
    $EXAS
    1/5/2026$105.00Outperform → In-line
    Evercore ISI
    Insulet Corporation
    $PODD
    12/16/2025$370.00Outperform
    Evercore ISI
    More analyst ratings

    $EXAS
    $PODD
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/3/26 4:19:18 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Weatherman Elizabeth H was granted 1,660 shares, increasing direct ownership by 32% to 6,902 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    5/21/26 4:40:42 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Stonesifer Timothy C. was granted 1,660 shares, increasing direct ownership by 36% to 6,251 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    5/21/26 4:39:04 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Insulet Announces U.S. Rollout of Enhanced Omnipod® 5 Algorithm and Expands Compatibility with Abbott's FreeStyle Libre 3 Plus Sensor

    Enhanced algorithm with new 100 mg/dL Target Glucose and improved alarm handling helps users improve time in range and stay in Automated Mode longer Omnipod 5 is now compatible with Abbott's Libre 3 Plus sensor in U.S., giving users more choice in how they manage their diabetes New features are designed to improve outcomes, reduce diabetes burden, and unlock barriers to AID technology to meet the needs of people with diabetes Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the U.S. rollout of new algorithm enhancements for the Omnipod 5 Automated Insulin Delivery

    6/3/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Participate in William Blair 46th Annual Growth Stock Conference

    Insulet Corporation (NASDAQ:PODD), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced that management will present at the William Blair 46th Annual Growth Stock Conference in Chicago on Wednesday, June 3, 2026 at 2:00 p.m. (Central Time). The live webcast and replay of the presentation will be accessible on the Insulet Investor Relations website: investors.insulet.com/events. About Insulet Corporation: Insulet Corporation (NASDAQ:PODD), headquartered in Massachusetts, is an innovative medical device company dedicated to simplifying life for people with diabetes and other conditions through its Omnipod product platform. The Omnipo

    5/27/26 4:05:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Initiates Voluntary Medical Device Correction for Certain Omnipod® Pods in the U.S. and Affected International Markets

    Insulet Corporation, Inc. (NASDAQ:PODD) ("Insulet" or the "Company") today announced a voluntary Medical Device Correction for specific lots of Omnipod® 5, Omnipod DASH®, and Omnipod® Insulin Management System (Omnipod Eros) Pods due to a manufacturing issue, identified through ongoing product monitoring, that could result in insulin under-delivery. This action is separate from the voluntary Medical Device Correction issued on March 12, 2026 affecting certain Omnipod 5 Pods in the U.S. and includes certain Pod lots distributed in the U.S. and affected international markets. Pods not included in the affected lots remain safe to use. Insulet identified that some Pods from specific lots ma

    5/26/26 4:05:00 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Weatherman Elizabeth H bought $497,490 worth of shares (3,450 units at $144.20), increasing direct ownership by 50% to 10,352 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    6/3/26 4:19:18 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Director Minogue Michael R bought $499,847 worth of shares (2,030 units at $246.23) (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/26/26 7:05:23 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    President and CEO Mcevoy Ashley bought $1,029,205 worth of shares (4,300 units at $239.35), increasing direct ownership by 45% to 13,916 units (SEC Form 4)

    4 - INSULET CORP (0001145197) (Issuer)

    2/23/26 8:14:32 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    SEC Filings

    View All

    SEC Form SD filed by Insulet Corporation

    SD - INSULET CORP (0001145197) (Filer)

    5/28/26 4:05:39 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    5/26/26 4:06:27 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Corporation filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - INSULET CORP (0001145197) (Filer)

    5/21/26 4:03:22 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    William Blair resumed coverage on Insulet

    William Blair resumed coverage of Insulet with a rating of Outperform

    5/20/26 8:53:26 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Rothschild & Co Redburn with a new price target

    Rothschild & Co Redburn downgraded Insulet from Buy to Neutral and set a new price target of $220.00

    4/24/26 8:03:49 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet downgraded by Citigroup with a new price target

    Citigroup downgraded Insulet from Buy to Neutral and set a new price target of $230.00

    4/7/26 8:40:12 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Leadership Updates

    Live Leadership Updates

    View All

    Insulet Appoints Mike Panos as Chief Commercial Officer

    Insulet Corporation (NASDAQ:PODD) ("Insulet" or the "Company"), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Mike Panos as Executive Vice President, Chief Commercial Officer, effective immediately. In this role, Mr. Panos will lead Insulet's global commercial organization, reporting to President and Chief Executive Officer Ashley McEvoy. He will also be a member of the Executive Leadership Team. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330524787/en/ "We have a significant growth opportunity in front of us, driven by strong clinical outcomes

    3/30/26 8:30:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Quanterix Appoints Everett Cunningham as President and CEO Effective January 19, 2026

    Planned Leadership Transition Positions Company for Growth Company Expects to Exceed Revenue and Cash Guidance for the Full Year 2025 Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that its Board of Directors (the "Board") has appointed Everett Cunningham as the Company's next President and Chief Executive Officer and a member of the Board, effective January 19, 2026. Mr. Cunningham will succeed Masoud Toloue, who will continue to serve as Chief Executive Officer until Mr. Cunningham assumes the role on January 19, 2026. Following Mr. Cunningham

    1/8/26 4:30:00 PM ET
    $ARVN
    $DGX
    $EXAS
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Medical Specialities
    Biotechnology: Laboratory Analytical Instruments

    Quanterix Announces Board and Leadership Changes to Support Next Stage of Growth

    Appoints Garret Hampton and Alan Sachs to the Board Appoints William Donnelly as Executive Chair of the Board and Jeffrey Elliott as Lead Independent Director Quanterix Corporation ("Quanterix" or the "Company") (NASDAQ:QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced a series of leadership and governance enhancements designed to support the Company's next phase of growth. These changes include the appointment of two highly accomplished life sciences executives, Garret Hampton, Ph.D., and Alan Sachs, M.D., Ph.D., to the Company's Board of Directors, effective immediately. Dr. Hampton most recently served as

    11/20/25 4:15:00 PM ET
    $EXAS
    $IDYA
    $ILMN
    Medical Specialities
    Health Care
    Biotechnology: Pharmaceutical Preparations
    Industrial Machinery/Components

    $EXAS
    $PODD
    Financials

    Live finance-specific insights

    View All

    Insulet Reports First Quarter 2026 Results

    Raises Full Year Total Company Revenue Guidance Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced its financial results for the three months ended March 31, 2026. First Quarter Financial Highlights: Revenue of $761.7 million, up 33.9%, or 30.1% in constant currency1, and exceeded the high end of the Company's guidance range of 25% - 27% at constant currency rates Total Omnipod revenue of $758.4 million, rose 36.9%, or 33.0% in constant currency U.S. Omnipod revenue of $515.6 million, increased 28.3% International Omnipod revenue of $242.9 million, increased 59.4

    5/6/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet to Announce First Quarter 2026 Financial Results on May 6, 2026

    Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the first quarter of 2026 on Wednesday, May 6, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on the Investor Relations section of the Company's website at investors.insulet.com, "Events and Presentations," and will be archived for future replay. You may also access the live call by dialing (888) 770-7129 for domestic callers, or (929

    4/1/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Insulet Reports Fourth Quarter and Full Year 2025 Results

    Fourth Quarter 2025 Revenue Increase of 31% (29% Constant Currency1) and Full Year 2025 Revenue Increase of 31% Year-Over-Year (30% Constant Currency) Represents 10th Consecutive Year of 20% or More Constant Currency Revenue Growth Insulet Corporation (NASDAQ:PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced financial results for the three months and full year ended December 31, 2025. Fourth Quarter Financial Highlights: Revenue of $783.8 million, up 31.2%, or 29.0% in constant currency, and exceeded the high end of the Company's guidance range of 25% to 28% in constant currency Total Omnipod

    2/18/26 7:00:00 AM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    $EXAS
    $PODD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Exact Sciences Corporation

    SC 13G - EXACT SCIENCES CORP (0001124140) (Subject)

    11/13/24 2:58:53 PM ET
    $EXAS
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Insulet Corporation

    SC 13G/A - INSULET CORP (0001145197) (Subject)

    11/12/24 12:53:28 PM ET
    $PODD
    Medical/Dental Instruments
    Health Care

    Amendment: SEC Form SC 13G/A filed by Exact Sciences Corporation

    SC 13G/A - EXACT SCIENCES CORP (0001124140) (Subject)

    11/8/24 10:52:39 AM ET
    $EXAS
    Medical Specialities
    Health Care